Page last updated: 2024-11-12

lansoprazole sulfone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10385385
CHEMBL ID4520193
SCHEMBL ID106666
MeSH IDM0534048

Synonyms (39)

Synonym
lansoprazole sulphone
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfonyl]-1h-benzimidazole
ag 1813
FT-0670723
ag-1813
lansoprazole sulfone
1h-benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfonyl)-
unii-a62faw18p1
a62faw18p1 ,
131926-99-3
AKOS015914410
SCHEMBL106666
lansoprazole impurity b [ep impurity]
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfonyl]-1h-benzimidazole
lansoprazole sultone
AC-30440
A1-04640
DTXSID80157268
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfonyl)-1h-1,3-benzodiazole
lansoprazole ep impurity b (lansoprazole sulfone)
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfonyl}-1h-1,3-benzodiazole
AS-74241
CHEMBL4520193
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfonyl)-1h-benzo[d]imidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphonyl]-1h-benzimidazole (lansoprazole sulphone)
J-006088
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfonyl]-1h-benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl} sulfonyl)-1h-1,3-benzimidazole
BCP17469
F19472
1h-benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfonyl]-
Q27273677
B0064-302135
discontinued see: l175026
A899118
tvmjmcgrssssdj-uhfffaoysa-n
CS-W009330
lansoprazolesulfone-d4
HY-W008614

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The mean Cmax and area under the curve (AUC) values of (+)-lansoprazole were 4-5 times greater than those of (-)-lansoprazole following oral administration of 30-mg racemic lansoprazole to dogs."( Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Arimori, K; Fujii, J; Hamada, A; Masa, K; Nakano, M, 2001
)
0.31
"05) in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs."( Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N, 2004
)
0.32
" To test differences in pharmacokinetic parameters among the three groups, analysis of variance (ANOVA) after log-transformation of data was used."( The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Chen, WL; Chu, NN; Li, XN; Xu, HR, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of lansoprazole might, to some extent, be increased through inhibition of P-glycoprotein during clarithromycin treatment."( Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Munakata, A; Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The experiments had a randomized cross-over design with a two-week washout period between dosing regimens."( Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
Arimori, K; Fujii, J; Masa, K; Miyamoto, S; Nakano, M; Nakayama, T, 1999
)
0.3
" Dose-response studies on gastroprotection in stress and indomethacin-induced ulcer and inhibition of pylorus ligation-induced acid secretion indicate that omeprazole significantly blocks gastric lesions at lower dose (2."( A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical.
Ali, E; Bandyopadhyay, U; Banerjee, RK; Biswas, K; Chattopadhyay, I; Varadaraj, A, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (14.29)18.2507
2000's14 (66.67)29.6817
2010's4 (19.05)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.06 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (47.62%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (52.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]